(S)-6-(3-Chloro-2-fluorobenzyl)-1-(1-hydroxy-3-methylbutan-2-yl)-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid

• CAS: 697761-98-1
• Catalog Number: ACM697761981
• Category: Other Products
• Molecular Weight: 447.888
• Molecular Formula: C₂₃H₂₃ClFNO₅
• Synonyms: (S)-6-(3-CHLORO-2-FLUOROBENZYL)-1-(1-HYDROXY-3-METHYLBUTAN-2-YL)-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID;(S)-6-(3-CHLORO-2-FLUOROBENZYL)-1-(1-HYDROXY-2,3-DIMETHYLBUTAN-2-YL)-7-METHOXY-4-OXO-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID;Elvitegravir(GS-9137,JTK-303);Elvitegravir;6-(3-Chloro-2-fluorobenzyl)-1-[1(S)-(hydroxymethyl)-2-methylpropyl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;(S)-6-(3-CHLORO-2-FLUOROBENZYL)-1-(1-HYDROXY-3-METHYLBUTAN-2-YL)-7-METHOXY-4-OXO;6-[(3-chloro-2-fluorophenyl)Methyl]-1-[(2S)-1-hydroxy-2,3-diMethylbutan-2-yl]-7-Methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid;GS 9137
• Melting Point: 93-96°C

Custom Q&A

What is the molecular formula of Elvitegravir?

The molecular formula of Elvitegravir is C23H23ClFNO5.

What is the molecular weight of Elvitegravir?

The molecular weight of Elvitegravir is 447.9 g/mol.

What is the IUPAC name of Elvitegravir?

The IUPAC name of Elvitegravir is 6-[(3-chloro-2-fluorophenyl)methyl]-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxoquinoline-3-carboxylic acid.

What is the Synonyms of Elvitegravir?

The synonyms of Elvitegravir are Elvitegravir, 697761-98-1, GS-9137, JTK-303, and Vitekta.

What is the CAS number of Elvitegravir?

The CAS number of Elvitegravir is 697761-98-1.

What is the chemical category of Elvitegravir?

Elvitegravir is a quinolinemonocarboxylic acid, an organofluorine compound, an aromatic ether, a quinolone, and a member of monochlorobenzenes.

What is the role of Elvitegravir?

Elvitegravir is a HIV-1 integrase inhibitor and is used in combination therapy for the treatment of HIV-1 infection.

How does Elvitegravir work?

Elvitegravir is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) that prevents the integration of HIV-1 DNA into the host genome, blocking the formation of the HIV-1 provirus and the propagation of the viral infection.

When was Elvitegravir first licensed and developed?

Elvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences.

How is Elvitegravir administered?

Elvitegravir is available as a single dose tablet and must be used in combination with an HIV protease inhibitor coadministered with ritonavir and another antiretroviral drug.